Ryan Schachne represents market-leading companies and business leaders in federal class action securities litigations and other complex commercial litigation matters.
Ryan defends financial institutions, large publicly traded companies, and their senior directors and officers in securities class action litigations, complex commercial litigations, and M&A litigation.
He has a strong track record of securing early and favorable results on behalf of his clients, including via settlement, motion practice, and, when necessary, trial.
Ryan maintains an active pro bono practice, representing clients in connection with immigration matters and discriminatory housing practices.
While at the New York University School of Law, Ryan was a staff development editor of the Review of Law and Social Change and interned with the Federal Defenders of New York.
Ryan’s relevant experience includes:
Trials
Shareholder Class Actions
Latham litigators were recognized for securing a complete dismissal of all claims for Carvana in a stockholder derivative complaint, and for securing a dismissal in full for vaccine maker Sinovac Biotech in a shareholder class action.
Latham team recognized for knocking out shareholder claims against client Sinovac Biotech.
Latham recognized for securing the complete dismissal of a federal securities stock drop case for Frequency Therapeutics Inc. and certain of its senior executives.